DeepMed Research

SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Completed

Conditions: Influenza (Healthy Volunteers)

Interventions: Biological: Quadrivalent Influenza Vaccine
Biological: High-Dose Quadrivalent Influenza Vaccine

First Posted Date: 2022-10-06

Last Posted Date: 2024-03-13

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1001

Registration Number: NCT05568979

Locations: 🇫🇮
Investigational Site Number : 2-2-002, Helsinki, Finland
🇫🇮
Investigational Site Number : 2-2-005, Jyväskylä, Finland
🇫🇮
Investigational Site Number : 2-2-003, Tampere, Finland

and more 12 locations

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Phase 1

Completed

Conditions: Influenza Immunization

Interventions: Biological: Quadrivalent Influenza mRNA Vaccine MRT5407
Biological: Quadrivalent Influenza Standard Dose Vaccine
Biological: Quadrivalent Influenza High-Dose Vaccine
Biological: Quadrivalent Recombinant Influenza Vaccine

First Posted Date: 2022-09-23

Last Posted Date: 2025-01-24

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 560

Registration Number: NCT05553301

Locations: 🇺🇸
Indago Research and Health Center Site Number : 8400014, Hialeah, Florida, United States
🇺🇸
Cenexel Research Centers of America Site Number : 8400048, Hollywood, Florida, United States
🇺🇸
Dade Research Center Site Number : 8400011, Miami, Florida, United States

and more 22 locations

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Phase 3

Terminated

Conditions: Influenza Immunization

Interventions: Biological: Quadrivalent influenza vaccine (IIV4)
Biological: Recombinant influenza vaccine (RIV4)

First Posted Date: 2022-08-24

Last Posted Date: 2024-07-24

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 366

Registration Number: NCT05513391

Locations: 🇺🇸
Velocity Clinical Research Omaha Site Number : 8400009, Omaha, Nebraska, United States
🇺🇸
Velocity Clinical Research Lincoln Site Number : 8400013, Lincoln, Nebraska, United States
🇺🇸
Rainbow Pediatrics Site Number : 8400014, Barnwell, South Carolina, United States

and more 28 locations

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Phase 3

Completed

Conditions: Influenza Immunization

Interventions: Biological: Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH

First Posted Date: 2022-08-23

Last Posted Date: 2024-05-30

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1308

Registration Number: NCT05513053

Locations: 🇺🇸
Rainbow Pediatrics Site Number : 8400014, Barnwell, South Carolina, United States
🇵🇱
Investigational Site Number : 6160007, Bydgoszcz, Kujawsko-pomorskie, Poland
🇺🇸
The Children's Clinic Of Jonesboro PA Site Number : 8400025, Jonesboro, Arkansas, United States

and more 32 locations

Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life

Phase 3

Completed

Conditions: RSV Immunization
Healthy Volunteer

Interventions: Biological: Nirsevimab

First Posted Date: 2022-06-29

Last Posted Date: 2025-05-08

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 8057

Registration Number: NCT05437510

Locations: 🇫🇷
Investigational Site 2500041, Aix-en-Provence, France
🇫🇷
Investigational Site Number: 2500014, Bordeaux, France
🇫🇷
Investigational Site Number: 2500019, Bron, France

and more 237 locations

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

Phase 1

Completed

Conditions: Influenza Immunization
Healthy Volunteers

Interventions: Biological: mRNA NA vaccine
Biological: High Dose Quadrivalent Influenza Vaccine

First Posted Date: 2022-06-21

Last Posted Date: 2024-01-31

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 233

Registration Number: NCT05426174

Locations: 🇺🇸
Central Phoenix Medical Clinic, LLC_Site: 8400010, Phoenix, Arizona, United States
🇺🇸
Optimal Research San Diego, LLC_Site: 8400009, San Diego, California, United States
🇺🇸
Synexus Clinical Research_Site 8400003, Cincinnati, Ohio, United States

and more 3 locations

Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

Phase 3

Completed

Conditions: Influenza (Healthy Volunteers)

Interventions: Biological: Quadrivalent inactivated influenza vaccine (IIV4)
Biological: Quadrivalent Recombinant Influenza Vaccine (RIV4)

First Posted Date: 2021-12-06

Last Posted Date: 2023-10-02

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 301

Registration Number: NCT05144945

Locations: 🇰🇷
Investigational Site Number :4100003, Ansan-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Investigational Site Number :4100001, Seoul, Seoul-teukbyeolsi, Korea, Republic of
🇰🇷
Investigational Site Number :4100002, Seoul, Korea, Republic of

Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne
Acne Vulgaris

Interventions: Drug: ORG101PL - Placebo 1
Drug: ORG101 - Experimental 1

First Posted Date: 2021-11-23

Last Posted Date: 2024-01-24

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 38

Registration Number: NCT05131373

Locations: 🇩🇪
Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB), Bochum, North Rhine-Westphalia, Germany
🇩🇪
UKSH, Campus Lübeck, Lübeck, Schleswig-Holstein, Germany
🇩🇪
Universitätsklinikum Frankfurt, Frankfurt, Hesse, Germany

and more 3 locations

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Completed

Conditions: Influenza (Healthy Volunteers)

Interventions: Biological: Quadrivalent Influenza Vaccine
Biological: High-Dose Quadrivalent Influenza Vaccine

First Posted Date: 2021-10-14

Last Posted Date: 2023-03-24

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1804

Registration Number: NCT05078060

Locations: 🇩🇪
Investigational Site Number :2760003, Grafenrheinfeld, Germany
🇩🇪
Investigational Site Number :2760007, Frankfurt am Main, Germany
🇩🇪
Investigational Site Number :2760006, Hamburg, Germany

and more 12 locations

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Phase 4

Completed

Conditions: Healthy Volunteers
Influenza Immunization

Interventions: Biological: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation
Biological: Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation

First Posted Date: 2021-09-20

Last Posted Date: 2023-10-03

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 90

Registration Number: NCT05050318

Locations: 🇺🇸
Investigational Site Number :8400002, Salt Lake City, Utah, United States
🇺🇸
Investigational Site Number :8400001, Bardstown, Kentucky, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy